Assignee
LUDWIG INST FOR CANCER RES LTD
CH·47 granted patents·35 pending applications·136 citations·filing 2004–2025
Top patents by PatentIndex Score
82 records- 0196US9518112B2TGF-β1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2013·Granted Dec 13, 2016·24 cites·20 claims
- 0293US11957751B2TGF-β1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2021·Granted Apr 16, 2024·2 cites·29 claims
- 0393US11306355B2Bisulfite-free, base-resolution identification of cytosine modificationsLUDWIG INST FOR CANCER RES LTD·Filed 2021·Granted Apr 19, 2022·6 cites·14 claims
- 0493US10000572B2Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibodyLUDWIG INST FOR CANCER RES LTD·Filed 2014·Granted Jun 19, 2018·22 cites·8 claims
- 0592US10947303B2TGF-ß1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 16, 2021·4 cites·14 claims
- 0692US7767792B2Antibodies to EGF receptor epitope peptidesLUDWIG INST FOR CANCER RES LTD·Filed 2005·Granted Aug 3, 2010·32 cites·17 claims
- 0791US7879981B2Breast, gastric and prostate cancer associated antigens and uses thereforLUDWIG INST FOR CANCER RES LTD·Filed 2008·Granted Feb 1, 2011·33 cites·10 claims
- 0886US10039715B2Liposomal formulation of nonglycosidic ceramides and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2016·Granted Aug 7, 2018·2 cites·21 claims
- 0984US2024117073A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 1083US10765648B2iNKT cell modulators and methods of using the sameLUDWIG INST FOR CANCER RES LTD·Filed 2019·Granted Sep 8, 2020·1 cites·28 claims
- 1183US10508303B2Whole-genome and targeted haplotype reconstructionLUDWIG INST FOR CANCER RES LTD·Filed 2014·Granted Dec 17, 2019·3 cites·18 claims
- 1283US2025011861A1Bisulfite-free, base-resolution identification of cytosine modificationsLUDWIG INST FOR CANCER RES LTD·Filed 2024·Application pending·0 cites
- 1382US2026053803A1Kinase mutants and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2025·Application pending·0 cites
- 1482US2025066850A1Whole-genome haplotype reconstructionLUDWIG INST FOR CANCER RES LTD·Filed 2024·Application pending·0 cites
- 1581US12221477B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2022·Granted Feb 11, 2025·0 cites·36 claims
- 1680US2024096441A1Genome-wide identification of chromatin interactionsLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 1779US10314796B2iNKT cell modulators and methods of using the sameLUDWIG INST FOR CANCER RES LTD·Filed 2017·Granted Jun 11, 2019·2 cites·26 claims
- 1877US11987843B2Bisulfite-free, base-resolution identification of cytosine modificationsLUDWIG INST FOR CANCER RES LTD·Filed 2022·Granted May 21, 2024·0 cites·18 claims
- 1977US11959136B2Bisulfite-free, base-resolution identification of cytosine modificationsLUDWIG INST FOR CANCER RES LTD·Filed 2022·Granted Apr 16, 2024·0 cites·17 claims
- 2077US10723793B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2016·Granted Jul 28, 2020·1 cites·18 claims
- 2174US7998483B2Lage-1 tumor associated nucleic acidsLUDWIG INST FOR CANCER RES LTD·Filed 2009·Granted Aug 16, 2011·0 cites·4 claims
- 2272US12173370B2Whole-genome haplotype reconstructionLUDWIG INST FOR CANCER RES LTD·Filed 2021·Granted Dec 24, 2024·0 cites·19 claims
- 2372US11485780B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Nov 1, 2022·0 cites·16 claims
- 2472US11441169B2Methods of small-RNA transcriptome sequencing and applications thereofLUDWIG INST FOR CANCER RES LTD·Filed 2017·Granted Sep 13, 2022·1 cites·16 claims
- 2572US11149311B2Whole-genome haplotype reconstructionLUDWIG INST FOR CANCER RES LTD·Filed 2019·Granted Oct 19, 2021·0 cites·22 claims
- 2672US7989587B2SSX-2 peptides presented by HLA class II moleculesLUDWIG INST FOR CANCER RES LTD·Filed 2008·Granted Aug 2, 2011·1 cites·8 claims
- 2771US12071660B2Bisulfite-free, base-resolution identification of cytosine modificationsLUDWIG INST FOR CANCER RES LTD·Filed 2019·Granted Aug 27, 2024·0 cites·19 claims
- 2871US2021032366A1Methods of treating neoplastic astrocytomaLUDWIG INST FOR CANCER RES LTD·Filed 2020·Application pending·0 cites
- 2970US11230603B2Anti-GARP proteinLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Jan 25, 2022·0 cites·15 claims
- 3067US7563870B2LAGE-1 tumor associated nucleic acidsLUDWIG INST FOR CANCER RES LTD·Filed 2004·Granted Jul 21, 2009·0 cites·6 claims
- 3166US10676527B2Methods and compositions for modulation of blood-neural barrierLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Jun 9, 2020·0 cites·5 claims
- 3266US10604579B2Antibody against a complex between human GARP and latent TGF-βLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 31, 2020·0 cites·5 claims
- 3366US2025290122A1Typing and Assembling Discontinuous Genomic ElementsLUDWIG INST FOR CANCER RES LTD·Filed 2025·Application pending·0 cites
- 3465US10266894B2Methods and compositions for cDNA synthesis and single-cell transcriptome profiling using template switching reactionLUDWIG INST FOR CANCER RES LTD·Filed 2014·Granted Apr 23, 2019·1 cites·24 claims
- 3565US2025201335A1Methods and systems for analyzing chromatinsLUDWIG INST FOR CANCER RES LTD·Filed 2023·Application pending·0 cites
- 3662US7910696B2Ssx-2 peptides presented by hla class II moleculesLUDWIG INST FOR CANCER RES LTD·Filed 2004·Granted Mar 22, 2011·0 cites·15 claims
- 3761US9926372B2Methods and compositions for modulation of blood-neural barrierLUDWIG INST FOR CANCER RES LTD·Filed 2016·Granted Mar 27, 2018·0 cites·22 claims
- 3861US2018057606A1Methods of treating meningiomaLUDWIG INST FOR CANCER RES LTD·Filed 2017·Application pending·0 cites
- 3961US2014322130A1Specific binding proteins and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2014·Application pending·0 cites
- 4060US11748885B2Methods and systems for analyzing time ordered image dataLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Sep 5, 2023·1 cites·40 claims
- 4160US2011159017A1Trytophan catabolism in cancer treatment and diagnosisLUDWIG INST FOR CANCER RES LTD·Filed 2009·Application pending·0 cites
- 4259US2009136446A1Induction of regulatory t cell-resistant helper cd4+ t cellsLUDWIG INST FOR CANCER RES LTD·Filed 2008·Application pending·0 cites
- 4358US8008464B2SSX-4 peptides presented by HLA class II moleculesLUDWIG INST FOR CANCER RES LTD·Filed 2010·Granted Aug 30, 2011·0 cites·11 claims
- 4458US7998718B2Identification and functional characterization of a novel ribosomal S6 protein kinaseLUDWIG INST FOR CANCER RES LTD·Filed 2004·Granted Aug 16, 2011·0 cites·11 claims
- 4558US2024335394A1Use Of Methanol And Prodrugs Thereof In TherapyLUDWIG INST FOR CANCER RES LTD·Filed 2022·Application pending·0 cites
- 4657US2024327491A1T cell receptors specific for tumor-associated antigens and methods of use thereofLUDWIG INST FOR CANCER RES LTD·Filed 2022·Application pending·0 cites
- 4757US2019203203A1Genome-wide identification of chromatin interactionsLUDWIG INST FOR CANCER RES LTD·Filed 2017·Application pending·0 cites
- 4856US12503504B2Humanized and variant TGF-β1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2019·Granted Dec 23, 2025·0 cites·28 claims
- 4956US7803382B2Method for inducing immune response to NY-CO-58LUDWIG INST FOR CANCER RES LTD·Filed 2004·Granted Sep 28, 2010·0 cites·4 claims
- 5055US12195556B2Reversible protein multimers, methods for their production and useLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Jan 14, 2025·0 cites·18 claims
Showing the top 50 of 82 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when LUDWIG INST FOR CANCER RES LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →